Gland Pharma Xiao Le as Chief appointed
Gland Pharma (BSE: GLAND) said Xiao Le as Chief has been appointed. The company is valued at about ₹55,097 crore.
What happened
Gland Pharma (BSE: GLAND) informed the stock exchanges on 9 November 2026 at 09:55 AM that Xiao Le as Chief has been appointed.
Company snapshot
Gland Pharma is a mid-cap company in the Healthcare sector, with a market value of about ₹55,097 crore.
The stock last traded at ₹3,339, against a 52-week range of ₹1,573.6–₹3,208.6 (4.1% above the high).
Before this filing the shares had moved +0.6% over the month and +21.9% over three months. Average daily turnover over the last 20 sessions was about ₹107 crore.
Promoters held 45.75% at the end of Q2 FY27, down 6.02% points from the previous quarter. Foreign institutions owned 10.36% and domestic institutions 33.21%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 1,487 | 183.7 | 11.15 |
| Q3 FY26 | 1,695 | 261.5 | 15.87 |
| Q4 FY26 | 1,743 | 366.7 | 22.26 |
| Q1 FY27 | 1,800 | 317 | 19.23 |
| Q2 FY27 | 1,834 | 290.8 | 17.62 |
What history shows
This is not the company's first management change disclosure: BCEIE has 9 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 0.4% on average the next trading day and was up 0.4% on average after five days (6 filings with price data).
Across 121 similar disclosures by other Healthcare companies, shares moved +1.1% on average the next day and +1.8% over five days; 50% of them rose the next day.
Market-wide, 4,332 management change filings with an impact score of 50 or more saw an average next-day move of −0.0%, with 45% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 30 Oct 2026 | Appointment of Chief Executive Officer for Gland Pharma… | +2.0% | — |
| 1 Oct 2026 | Resignation of Mr. Wenjie Zhang as a Non-Executive & Non-Independent… | +4.6% | — |
| 14 Aug 2026 | Management change | −1.9% | −5.0% |
| 20 Jul 2026 | Change in Director(s) of the company. | −0.8% | −1.3% |
What to watch
- The appointment of a successor and any change in strategy or guidance.
In the news
Recent coverage elsewhere (links open the original publisher):
- Gland Pharma Share Price
- Gland Pharma Q2 Results: Net profit jumps 58% on strong business execution, CDMO revenue up 31% - CNBC TV18
- Gland Pharma Q2 FY27 Profit Jumps 58% as CDMO Grows 31%
- Gland Pharma Limited (GLAND.NS) Stock Price, News, Quote & History
- Gland Pharma names Ajay Sahni CEO of Singapore subsidiary
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.